A COVID-19 vaccine developed by AstraZeneca and the University of Oxford found encouraging results following a U.S. trial, which could mean another weapon is on the way in the fight to end the pandemic.
The vaccine was found to be 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization in a report released on Monday.
The safety and efficacy analysis was based on 32,449 participants across 88 trial centers in the U.S., Peru and Chile.
Data from the late-stage human trial study reaffirms that the Oxford-AstraZeneca vaccine is safe and highly effective.
“We are thrilled by the results we have disclosed this morning,” Ruud Dobber, executive vice president of AstraZeneca’s biopharmaceuticals business unit, told CNBC’s “Squawk Box” on Monday.
“The plan is to file in the first half of April for the emergency use authorization and, of course, then it is in the hands of the FDA how fast they can decide about the approval. Assuming that the approval will take place in a fast way, we hope to deliver 30 million doses instantly after the EUA for Americans to get vaccinated,” Dobber said.
Already on the market in the U.S.:
- Moderna’s vaccine has been found to be more than 94% effective in preventing COVID.
- Pfizer-BioNTech’s vaccine was found to be 95% effective.
- Johnson&Johnson was found to be 79% effective.
Its vaccine endured some controversy after several countries suspended its use following reports of blood clots in some vaccinated people, to the dismay of some health experts.
Germany, France, Italy and Spain, among others, have resumed use of the Oxford-AstraZeneca vaccine after Europe’s drug regulator concluded the shot is safe and effective.
Additionally, the World Health Organization and the International Society on Thrombosis and Hemostasis recommended continued use of the vaccine.